» Articles » PMID: 26486970

An Approach to the Immunophenotypic Features of Circulating CD4⁺NKG2D⁺ T Cells in Invasive Cervical Carcinoma

Abstract

Background: NKG2D, an activating immunoreceptor, is primarily restricted to NK cells and CD8(+) T cells. The existence of an atypical cytotoxic CD4(+)NKG2D(+) T cell population has also been found in patients with autoimmune dysfunctions. Nonetheless, contradictory evidence has categorized this population with a regulatory rather than cytotoxic role in other situations. These confounding data have led to the proposal that two distinct CD4(+)NKG2D(+) T cell subsets might exist. The immune response elicited in cervical cancer has been characterized by apparent contradictions concerning the role that T cells, in particular T-helper cells, might be playing in the control of the tumor growth. Interestingly, we recently reported a substantial increase in the frequency of CD4(+)NKG2D(+) T cells in patients with cervical intraepithelial neoplasia grade-1. However, whether this particular population is also found in patients with more advanced cervical lesions or whether they express a distinctive phenotype remains still to be clarified. In this urgent study, we focused our attention on the immunophenotypic characterization of CD4(+)NKG2D(+) T cells in patients with well-established cervical carcinoma and revealed the existence of at least two separate CD4(+)NKG2D(+) T cell subsets defined by the co-expression or absence of CD28.

Results: Patients with diagnosis of invasive cervical carcinoma were enrolled in the study. A group of healthy individuals was also included. Multicolor flow cytometry was used for exploration of TCR alpha/beta, CD28, CD158b, CD45RO, HLA-DR, CD161, and CD107a. A Luminex-based cytokine kit was used to quantify the levels of pro- and anti-inflammatory cytokines. We found an increased percentage of CD4(+)NKG2D(+) T cells in patients with cervical cancer when compared with controls. Accordingly with an increase of CD4(+)NKG2D(+) T cells, we found decreased CD28 expression. The activating or degranulation markers HLA-DR, CD161, and CD107a were heterogeneously expressed. The levels of IL-1beta, IL-2, TNF-alpha, and IL-10 were negatively correlated with the percentages of CD4(+)NKG2D(+) T cells in patients with cervical carcinoma.

Conclusions: Taken together, our results reveal the existence of two separate CD4(+)NKG2D(+) T cell subsets defined by the co-expression or absence of CD28, the latter more likely to be present in patients with cervical cancer.

Citing Articles

Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.

Rocha Martins P, Morais K, Galdino N, Jacauna A, Paula S, Magalhaes W Sci Rep. 2023; 13(1):22634.

PMID: 38114557 PMC: 10730812. DOI: 10.1038/s41598-023-49441-2.


Senescent T cells: Beneficial and detrimental roles.

Laphanuwat P, Gomes D, Akbar A Immunol Rev. 2023; 316(1):160-175.

PMID: 37098109 PMC: 10952287. DOI: 10.1111/imr.13206.


A Comprehensive View of the Cancer-Immunity Cycle (CIC) in HPV-Mediated Cervical Cancer and Prospects for Emerging Therapeutic Opportunities.

Pena Avila J, Carvalho B, Coimbra E Cancers (Basel). 2023; 15(4).

PMID: 36831674 PMC: 9954575. DOI: 10.3390/cancers15041333.


CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.

Huang X, Liu W, Liu C, Hu J, Wang B, Ren A Front Mol Biosci. 2023; 9:983410.

PMID: 36589225 PMC: 9798917. DOI: 10.3389/fmolb.2022.983410.


Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment.

Zhu S, Wang Y, Tang J, Cao M Front Immunol. 2022; 13:1074477.

PMID: 36532071 PMC: 9753984. DOI: 10.3389/fimmu.2022.1074477.


References
1.
Richie Ehrlich L, Ogasawara K, Hamerman J, Takaki R, Zingoni A, Allison J . Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol. 2005; 174(4):1922-31. DOI: 10.4049/jimmunol.174.4.1922. View

2.
van Leeuwen E, Remmerswaal E, Vossen M, Rowshani A, Wertheim-van Dillen P, van Lier R . Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol. 2004; 173(3):1834-41. DOI: 10.4049/jimmunol.173.3.1834. View

3.
Segovis C, Schoon R, Dick C, Nacusi L, Leibson P, Billadeau D . PI3K links NKG2D signaling to a CrkL pathway involved in natural killer cell adhesion, polarity, and granule secretion. J Immunol. 2009; 182(11):6933-42. PMC: 2706535. DOI: 10.4049/jimmunol.0803840. View

4.
Azimi N, Jacobson S, Tanaka Y, Corey L, Groh V, Spies T . Immunostimulation by induced expression of NKG2D and its MIC ligands in HTLV-1-associated neurologic disease. Immunogenetics. 2006; 58(4):252-8. DOI: 10.1007/s00251-006-0082-9. View

5.
Martens P, Goronzy J, Schaid D, Weyand C . Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997; 40(6):1106-14. DOI: 10.1002/art.1780400615. View